Human Genome Epidemiology Literature Finder
|
Records 1 - 7 (of 7 Records) |
| Query Trace: Neutropenia and MYD88[original query] |
|---|
| Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood 2014 Jul 124 (4): 503-10. Treon Steven P, Tripsas Christina K, Meid Kirsten, Kanan Sandra, Sheehy Patricia, Chuma Stacey, Xu Lian, Cao Yang, Yang Guang, Liu Xia, Patterson Christopher J, Warren Diane, Hunter Zachary R, Turnbull Barry, Ghobrial Irene M, Castillo Jorge |
| Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. British journal of haematology 2017 8 179 (1): 98-105. Paludo Jonas, Abeykoon Jithma P, Kumar Shaji, Shreders Amanda, Ailawadhi Sikander, Gertz Morie A, Kourelis Taxiarchis, King Rebecca L, Reeder Craig B, Leung Nelson, Kyle Robert A, Buadi Francis K, Habermann Thomas M, Dingli David, Witzig Thomas E, Dispenzieri Angela, Lacy Martha Q, Go Ronald S, Lin Yi, Gonsalves Wilson I, Warsame Rahma, Lust John A, Rajkumar S Vincent, Ansell Stephen M, Kapoor Prasha |
| Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 7 36 (27): 2755-2761. Treon Steven P, Gustine Joshua, Meid Kirsten, Yang Guang, Xu Lian, Liu Xia, Demos Maria, Kofides Amanda, Tsakmaklis Nicholas, Chen Jiaji G, Munshi Manit, Chan Gloria, Dubeau Toni, Raje Noopur, Yee Andrew, O'Donnell Elizabeth, Hunter Zachary R, Castillo Jorge |
| Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer science 2019 3 110 (5): 1686-1694. Munakata Wataru, Ando Kiyoshi, Hatake Kiyohiko, Fukuhara Noriko, Kinoshita Tomohiro, Fukuhara Suguru, Shirasugi Yukari, Yokoyama Masahiro, Ichikawa Satoshi, Ohmachi Ken, Gion Naokazu, Aoi Arata, Tobinai Kens |
| Venetoclax in Previously Treated Waldenström Macroglobulinemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 11 40 (1): 63-71. Castillo Jorge J, Allan John N, Siddiqi Tanya, Advani Ranjana H, Meid Kirsten, Leventoff Carly, White Timothy P, Flynn Catherine A, Sarosiek Shayna, Branagan Andrew R, Demos Maria G, Guerrera Maria L, Kofides Amanda, Liu Xia, Munshi Manit, Tsakmaklis Nicholas, Xu Lian, Yang Guang, Patterson Christopher J, Hunter Zachary R, Davids Matthew S, Furman Richard R, Treon Steven |
| Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement. Frontiers in immunology 2023 9 14 1219167. Hongzhi Geng, Sixun Jia, Ying Zhang, Jiaqi Li, Qin Yang, Liangyu Zeng, Xiangping Zong, Yutong Lu, Shuangzhu Lu, Jin Zhou, Caixia Li, Depei |
| Ibrutinib and venetoclax as primary therapy in symptomatic treatment naïve Waldenström macroglobulinemia. Blood 2023 11 . Jorge J Castillo, Andrew R Branagan, David Sermer, Catherine Flynn, Kirsten E Meid, Megan Little, Katherine Stockman, Timothy P White, Alexa G Canning, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nicholas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P Treon, Shayna Sarosi |
- Page last reviewed:Feb 1, 2024
- Content source: